KBKristina M. Boguslawski

Kristina M. Boguslawski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristina M. Boguslawski has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    All major cholesterol-dependent cytolysins use glycans as cellular receptors

    by Lucy K. Shewell, Christopher J. Day, Freda E.-C. Jen, Thomas Haselhorst, John M. Atack, Josephine F. Reijneveld, Arun Everest-Dass, David B. A. James, Kristina M. Boguslawski, Stephan Brouwer, et al.

    Cholesterol-dependent cytolysins (CDCs) form pores in cholesterol-rich membranes, but cholesterol alone is insufficient to explain their cell and host tropism. Here, we show that all eight major CDCs have high-affinity lectin activity that identifies glycans as candidate cellular receptors. Streptolysin O, vaginolysin, and perfringolysin O bind multiple glycans, while pneumolysin, lectinolysin, and listeriolysin O recognize a single glycan class. Addition of exogenous carbohydrate receptors for each CDC inhibits toxin activity. We present a structure for suilysin domain 4 in complex with two distinct glycan receptors, P1 antigen and αGal/Galili. We report a wide range of binding affinities for cholesterol and for the cholesterol analog pregnenolone sulfate and show that CDCs bind glycans and cholesterol independently. Intermedilysin binds to the sialyl-TF O-glycan on its erythrocyte receptor, CD59. Removing sialyl-TF from CD59 reduces intermedilysin binding. Glycan-lectin interactions underpin the cellular tropism of CDCs and provide molecular targets to block their cytotoxic activity.


  • Open Access

    Exploiting species specificity to understand the tropism of a human-specific toxin

    by K. M. Boguslawski, A. N. McKeown, C. J. Day, K. A. Lacey, K. Tam, N. Vozhilla, S. Y. Kim, M. P. Jennings, S. B. Koralov, N. C. Elde, et al.

    Many pathogens produce virulence factors that are specific toward their natural host. Clinically relevant methicillin-resistant Staphylococcus aureus (MRSA) isolates are highly adapted to humans and produce an array of human-specific virulence factors. One such factor is LukAB, a recently identified pore-forming toxin that targets human phagocytes by binding to the integrin component CD11b. LukAB exhibits strong tropism toward human, but not murine, CD11b. Here, phylogenetics and biochemical studies lead to the identification of an 11-residue domain required for the specificity of LukAB toward human CD11b, which is sufficient to render murine CD11b compatible with toxin binding. CRISPR-mediated gene editing was used to replace this domain, resulting in a “humanized” mouse. In vivo studies revealed that the humanized mice exhibit enhanced susceptibility to MRSA bloodstream infection, a phenotype mediated by LukAB. Thus, these studies establish LukAB as an important toxin for MRSA bacteremia and describe a new mouse model to study MRSA pathobiology.


  • Identification of biologic agents to neutralize the bicomponent leukocidins of Staphylococcus aureus

    by Rita Chan, Peter T. Buckley, Aidan O’malley, William E. Sause, Francis Alonzo, Ashira Lubkin, Kristina M. Boguslawski, Angela Payne, Jeffrey Fernandez, William R. Strohl, et al.

    Small protein biologics called centyrins can be engineered to combat the toxicity caused by systemic Staphylococcus aureus infection.